

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549-3628

October 31, 2013

#### Via E-Mail

Paul Strecker, Esq. Shearman & Sterling 12<sup>th</sup> Floor, Gloucester Tower, The Landmark 15 Queen's Road Central Hong Kong

**Re:** Amended Schedule 13E-3

Filed October 23, 2013 by Simcere Pharmaceutical Group et. al.

File No. 005-83690

Dear Mr. Strecker:

We have reviewed your filing and have the following comments.

## **Amended Schedule 13E-3**

1. We note your response to prior comment 2. Please tell us why Mr. John Huan Zhao is not an affiliate engaged, directly or indirectly, in the going private transaction.

#### **Revised Proxy Statement**

Special Factors

Reasons for the Merger and Recommendation of the Special Committee, page 35

2. Please disclose the substance of your response to prior comment 13.

Position of the Buyer Group as to the Fairness of the Merger, page 41

3. We note the deletion made in response to prior comment 18. Please tell us the reason you deleted the referenced bullet point. Did the Buyer Group not consider that factor? If so, why was it included in the original proxy statement?

Paul Strecker, Esq. Shearman & Sterling October 31, 2013 Page 2

### Certain Financial Projections, page 44

4. We reissue prior comment 20. We do not believe your disclosure of financial projections is made pursuant to Item 1015 of Regulation M-A and we note that the projections were prepared by the company management and shared with the financial advisor.

# Opinion of the Special Committee's Financial Advisor, page 47

5. We reissue the first sentence of prior comment 23. To the extent that the revised disclosure was intended to comply with our comment, please quantify the unlevered free cash flows and the range of terminal values and disclose the amount of each adjustment listed.

Please direct any questions to me at (202) 551-3619. You may also contact me via facsimile at (202) 772-9203. Please send all correspondence to us at the following ZIP code: 20549-3628.

Sincerely,

/s/ Daniel F. Duchovny
Daniel F. Duchovny
Special Counsel
Office of Mergers and Acquisitions